Evaluate the Efficacy and Safety of GZR101-80 Injection in Patients With Type 2 Diabetes
A phase 2 trial registered on ClinicalTrials.gov. The registry status is not yet recruiting. It plans to enroll 345 participants.
Also called NCT07387003
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; no masking; primary purpose treatment
- Phase
- Phase 2
- Enrolled
- 345 participants
- Sponsor
- Registry
-
NCT07387003
-
- Planned start
- (anticipated)
- Primary completion
- (anticipated)
- Completion
- (anticipated)
- Countries
- China
- Registry status
- Not yet recruiting
Technical summary
Registry record NCT07387003. Randomized; no masking; primary purpose treatment. Start 2026-04-10 (anticipated); primary completion 2027-02-11 (anticipated). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Evaluate the Efficacy and Safety of GZR101-80 Injection in Patients With Type 2 Diabetes
- Condition
- Type 2 Diabetes (T2DM)
- Intervention (Drug)
- GZR101-80
- Intervention (Drug)
- GZR33 or Insulin degludec/Insulin aspart or Insulin aspart30 (NovoRapid®30)
- Lead sponsor
- Gan & Lee Pharmaceuticals.
Record details
- Record id
cardio:ct-nct07387003- Content hash
d8ad54c1fc06f013de4c7c82e22feaaa3d54361fea09fc58f9e1643fb289e5d4